Patents by Inventor Carlos Forray

Carlos Forray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7132248
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: November 7, 2006
    Assignee: H. Lundbeck A/S
    Inventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
  • Patent number: 7060449
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: June 13, 2006
    Assignee: H. Lundbeck A/S
    Inventors: Kelli E. Smith, Christophe P. G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
  • Patent number: 6790656
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Grant
    Filed: June 4, 1998
    Date of Patent: September 14, 2004
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Kelli E. Smith, Christophe P. G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
  • Publication number: 20030215823
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Application
    Filed: October 31, 2002
    Publication date: November 20, 2003
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
  • Publication number: 20030129702
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Application
    Filed: November 18, 2002
    Publication date: July 10, 2003
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Kelli E. Smith, Christophe P.G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
  • Patent number: 6586191
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Grant
    Filed: July 23, 1997
    Date of Patent: July 1, 2003
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
  • Publication number: 20030082672
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Application
    Filed: July 23, 1997
    Publication date: May 1, 2003
    Inventors: KELLI E. SMITH, DAVID LINEMEYER, CHRISTOPHE GERALD, THERESA BRANCHEK, RICHARD L. WEINSHANK, CARLOS FORRAY
  • Publication number: 20030077701
    Abstract: This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.
    Type: Application
    Filed: December 20, 2001
    Publication date: April 24, 2003
    Inventors: Carlos Forray, John A. Salon, Thomas M. Laz, Raisa Nagorny, Amy E. Wilson
  • Patent number: 6083705
    Abstract: This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptors.
    Type: Grant
    Filed: December 7, 1998
    Date of Patent: July 4, 2000
    Assignee: Synaptic Pharmaceuticals Corporation
    Inventors: Jonathon A. Bard, Richard L. Weinshank, Carlos Forray
  • Patent number: 5972624
    Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising an isolated nucleic acid encoding a galanin receptor, cells comprising such vectors, antibodies directed to the galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding galanin receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid encoding a galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant galanin receptor, as well as methods of determining binding of compounds to the galanin receptor.
    Type: Grant
    Filed: April 1, 1996
    Date of Patent: October 26, 1999
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Kelli E. Smith, Christophe P. G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
  • Patent number: 5861309
    Abstract: This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.
    Type: Grant
    Filed: August 21, 1995
    Date of Patent: January 19, 1999
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Richard L. Weinshank, Carlos Forray
  • Patent number: 5714381
    Abstract: This invention provides an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 3, 1998
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Carlos Forray, Richard L. Weinshank
  • Patent number: 5556753
    Abstract: This invention provides an isolated nucleic acid molecule encoding a human .alpha..sub.1a adrenergic receptor, an isolated nucleic acid molecule encoding a human .alpha..sub.1b adrenergic receptor and an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor, an isolated protein which is a human .alpha..sub.1a adrenergic receptor, an isolated protein which is .alpha..sub.1b adrenergic receptor and a isolated protein which is a human .alpha..sub.1c adrenergic receptor, vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1a adrenergic receptor, vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1b adrenergic receptor, and vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor, mammalian cells comprising such vectors, antibodies directed to the human .alpha..sub.1a adrenergic receptor, antibodies directed to the human .alpha..sub.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: September 17, 1996
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Carlos Forray, Richard L. Weinshank